加载中
HKSEHealthcareMedical - Pharmaceuticals
最新数据
HK$2.765
+HK$0.05 · +1.84%
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
最新数据
HK$2.765
+HK$0.05 · +1.84%
盘中时间采用HKT。市场数据可能有所延迟。
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
日内区间
当前HK$2.765
52周区间
当前HK$2.765
盘中时间采用HKT。市场数据可能有所延迟。
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
日内区间
当前HK$2.765
52周区间
当前HK$2.765
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（HKD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 41.65亿 HKD | 57.73亿 HKD | 64.63亿 HKD | 64.34亿 HKD | 53.57亿 HKD |
| 销货成本 | 24.34亿 HKD | 28.65亿 HKD | 28.43亿 HKD | 29.94亿 HKD | 23.19亿 HKD |
| 毛利 | 17.31亿 HKD | 29.08亿 HKD | 36.2亿 HKD | 34.4亿 HKD | 30.38亿 HKD |
| 研究与开发 | 2.44亿 HKD | 2.66亿 HKD | 2.9亿 HKD | 2.59亿 HKD | 2.48亿 HKD |
| 销售、一般及管理费用 | 10.71亿 HKD | 14.49亿 HKD | 15.3亿 HKD | 19.45亿 HKD | 20.17亿 HKD |
| 营业费用 | 11.02亿 HKD | 15.65亿 HKD | 19.81亿 HKD | 21.44亿 HKD | 21.82亿 HKD |
| 利息收入 | 2112.4万 HKD | 2954.6万 HKD | 3392.4万 HKD | 2919.9万 HKD | 2470.7万 HKD |
| 利息支出 | 1.06亿 HKD | 1.27亿 HKD | 1.25亿 HKD | 8825万 HKD | 6129.8万 HKD |
| 折旧和摊销 | 4.53亿 HKD | 4.56亿 HKD | 4.06亿 HKD | 3.71亿 HKD | 3.9亿 HKD |
| 营业利润 | 6.29亿 HKD | 13.44亿 HKD | 16.39亿 HKD | 14.24亿 HKD | 9.88亿 HKD |
| 净利润 | 4.71亿 HKD | 10.61亿 HKD | 13.19亿 HKD | 11.23亿 HKD | 7.86亿 HKD |
公司数据更新于 2026年10月16日。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2012年9月24日 | 6:5 | — | — |
股票拆分 | 2007年8月29日 | 5:1 | — | — |
已生效 2012年9月24日
6:5
已生效 2007年8月29日
5:1
报告持有此股票敞口的交易所交易基金。
Vanguard Total International Stock ETFVXUS575.51万0.00%6657亿 USD0.05%US$83.84+0.31%
iShares Core MSCI Emerging Markets ETFIEMG571.65万0.00%1545.08亿 USD0.09%US$78.09-0.70%
Vanguard FTSE Emerging Markets ETFVWO521.05万0.00%1647亿 USD0.06%US$58.79-0.19%
Avantis Emerging Markets Equity ETFAVEM326.21万0.01%274.87亿 USD0.33%US$90.40-0.68%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS141.87万0.01%139亿 USD0.06%US$152.3-0.02%
iShares Core MSCI Total International Stock ETFIXUS84.78万0.00%577.6亿 USD0.07%US$93.89+0.35%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX63.38万0.10%6.66亿 USD0.65%US$70.3188-0.72%
Avantis Emerging Markets Value ETFAVES39.81万0.03%15.4亿 USD0.36%US$64.35+0.03%Vanguard Total International Stock ETFVXUSiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE Emerging Markets ETFVWOAvantis Emerging Markets Equity ETFAVEMVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares Core MSCI Total International Stock ETFIXUSState Street SPDR S&P Emerging Markets Small Cap ETFEWXAvantis Emerging Markets Value ETFAVESAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
